Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
| Status: | Completed |
|---|---|
| Conditions: | Colitis, Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | Any - 18 |
| Updated: | 4/21/2016 |
| Start Date: | September 2004 |
| End Date: | December 2008 |
Non Invasive Markers in the Diagnosis and Interval Assessment of Children and Adults With Known or Suspected Allergic Disease
The incidence of gastrointestinal allergy is on the rise and can be manifest in a number of
different clinical presentations. The goal of this study is to evaluate the measurement of
CD23, a protein that can be identified stool, urine, and blood, as a non-invasive marker for
use in the diagnosis and interval assessment of patients with known or suspected
gastrointerstianl allergy.
Eosinophilic esophagitis (EE) is a disorder typically found in school-age and adolescent
children, and is more prevalent in male patients. Patients with EE typically present with
symptoms of heartburn or difficulties swallowing. Blood and x-ray studies may be normal or
display non-specific findings. The diagnosis of EE rests on a combination of clinical
symptoms, and the results of endoscopic and histologic studies. There is currently no
biochemical marker that can be used to monitor disease course in these patients.
Cow milk protein intolerance (CMPI) is an allergic process affecting the distal
gastrointestinal tract in infants. As such, it often presents as diarrhea without or without
the presence of gross rectal bleeding in infants ranging in age from birth to 6 months of
age. Children display symptoms of abdominal disress including emesis, cramping, colic, or
feeding difficulties. The diagnosis is based on an appropriate clinical history and
supporting physical exam (typically normal). Treatment involves removal of the offending
dietary antigens which include cow or soy milk protein Eosinophilic crypt abscesses, or
collections of eosinophils within the intestine can also be seen.
CD23 is a protein that can be found on allergy-type white blood cells (eosinophils), as well
as on the cells that line the gastrointestinal tract. Previous studies have reported
increased levels of CD23 in infants with cow's milk allergy. CD23 is also elevated in
infants and children with allergic disease. Levels of CD23 appears to fall in conjunction
with therapy.
different clinical presentations. The goal of this study is to evaluate the measurement of
CD23, a protein that can be identified stool, urine, and blood, as a non-invasive marker for
use in the diagnosis and interval assessment of patients with known or suspected
gastrointerstianl allergy.
Eosinophilic esophagitis (EE) is a disorder typically found in school-age and adolescent
children, and is more prevalent in male patients. Patients with EE typically present with
symptoms of heartburn or difficulties swallowing. Blood and x-ray studies may be normal or
display non-specific findings. The diagnosis of EE rests on a combination of clinical
symptoms, and the results of endoscopic and histologic studies. There is currently no
biochemical marker that can be used to monitor disease course in these patients.
Cow milk protein intolerance (CMPI) is an allergic process affecting the distal
gastrointestinal tract in infants. As such, it often presents as diarrhea without or without
the presence of gross rectal bleeding in infants ranging in age from birth to 6 months of
age. Children display symptoms of abdominal disress including emesis, cramping, colic, or
feeding difficulties. The diagnosis is based on an appropriate clinical history and
supporting physical exam (typically normal). Treatment involves removal of the offending
dietary antigens which include cow or soy milk protein Eosinophilic crypt abscesses, or
collections of eosinophils within the intestine can also be seen.
CD23 is a protein that can be found on allergy-type white blood cells (eosinophils), as well
as on the cells that line the gastrointestinal tract. Previous studies have reported
increased levels of CD23 in infants with cow's milk allergy. CD23 is also elevated in
infants and children with allergic disease. Levels of CD23 appears to fall in conjunction
with therapy.
The incidence of gastrointestinal allergy is on the rise and can be manifest in a number of
different clinical presentations. The goal of this study is to evaluate the measurement of
CD23, a protein that can be identified stool, urine, and blood, as a non-invasive marker for
use in the diagnosis and interval assessment of patients with known or suspected
gastrointerstianl allergy.
Eosinophilic esophagitis (EE) is a disorder typically found in school-age and adolescent
children, and is more prevalent in male patients. Patients with EE typically present with
symptoms of heartburn or difficulties swallowing. Blood and x-ray studies may be normal or
display non-specific findings. The diagnosis of EE rests on a combination of clinical
symptoms, and the results of endoscopic and histologic studies. The endoscopic appearance of
esophageal mucosa in these patients is often pale and displays a poor vascular pattern. The
mucosa can be thickened in appearance. Esophagitis in patients with acid/peptic disease is
typically more pronounced at the bottom of the esophagus, in the region of the
gastroesophageal junction. In contrast, the mucosal disease observed in patients with EE is
often more pronouced in the proximal esophagus. Treatment may include topial steroids
(delivered systemically or via metered-dose inhaler) and formal allergy evaluation to detect
potential dietary triggers. Anti-allergic therapies, including monteleukostat, benedryl,
antihistimines, and cromolyn sodium have also been proposed as treatments for EE. Treatment
efficacy is determined by a combination of clinical report and serial endoscopic study.
There is currently no biochemical marker that can be used to monitor disease course in these
patients.
Cow milk protein intolerance (CMPI) is an allergic process affecting the distal
gastrointestinal tract in infants. As such, it often presents as diarrhea without or without
the presence of gross rectal bleeding in infants ranging in age from birth to 6 months of
age. Children display symptoms of abdominal disress including cramping, colic, or feeding
difficulties. Emesis after feeds may also be present. Affected children display loose and
more frequent bowel movements. Stools in these patients may contain mucus as well as
microscopic or visible blood. In most patients, the diagnosis is based on an appropriate
clinical history and supporting physical exam (typically normal). Treatment involves removal
of the offending dietary antigens which include cow or soy milk protein. A small percentage
of patients (< 5%) require formal endoscopic study. The mucosa in these patients appears
erythematous, friable, and can display a patchy distribution of inflammation. Histologic
exam reveals varying degrees of eosinophic infiltration of the intestinal tissue.
Eosinophilic crypt abscesses, or collections of eosinophils within the intestine can also be
seen. Patients responding to therapy will display normalization of stool frequency,
decreased symptoms of abdominal discomfort, and an absence of gross or microscopic
intestinal bleeding.
CD23 is a protein that can be found on allergy-type white blood cells (eosinophils), as well
as on the cells that line the gastrointestinal tract. Previous studies have reported
increased levels of CD23 in infants with cow's milk allergy. CD23 is also elevated in
infants and children with allergic disease, when compared to to children without apparent
atopic disease. Moreover, the level of CD23 appears to fall in conjunction with therapy.
The development of non-invasive markers of intestinal allergy would facilitate diagnosis as
well as provide clinicians with a tool to assess patients compliance and response to
therapy. The relationship between levels of serum, urinary, and fecal CD23 levels has not
been previously studied in patients with known or suspected intestinal allergy.
Subjects in this study will be asked to provide a blood, urine, and stool sample when they
present with symptoms or either cow milk protein intolerance or eosinophilic esophagitis.
Blood will only be obtained if clinical samples are requested, and no extra blood drawing
will be required for participation in this study. Similar blood, urine, and stool specimens
will be obtained after the patient has been placed on anti-atopic therapy and is
experiencing clinical remission.
different clinical presentations. The goal of this study is to evaluate the measurement of
CD23, a protein that can be identified stool, urine, and blood, as a non-invasive marker for
use in the diagnosis and interval assessment of patients with known or suspected
gastrointerstianl allergy.
Eosinophilic esophagitis (EE) is a disorder typically found in school-age and adolescent
children, and is more prevalent in male patients. Patients with EE typically present with
symptoms of heartburn or difficulties swallowing. Blood and x-ray studies may be normal or
display non-specific findings. The diagnosis of EE rests on a combination of clinical
symptoms, and the results of endoscopic and histologic studies. The endoscopic appearance of
esophageal mucosa in these patients is often pale and displays a poor vascular pattern. The
mucosa can be thickened in appearance. Esophagitis in patients with acid/peptic disease is
typically more pronounced at the bottom of the esophagus, in the region of the
gastroesophageal junction. In contrast, the mucosal disease observed in patients with EE is
often more pronouced in the proximal esophagus. Treatment may include topial steroids
(delivered systemically or via metered-dose inhaler) and formal allergy evaluation to detect
potential dietary triggers. Anti-allergic therapies, including monteleukostat, benedryl,
antihistimines, and cromolyn sodium have also been proposed as treatments for EE. Treatment
efficacy is determined by a combination of clinical report and serial endoscopic study.
There is currently no biochemical marker that can be used to monitor disease course in these
patients.
Cow milk protein intolerance (CMPI) is an allergic process affecting the distal
gastrointestinal tract in infants. As such, it often presents as diarrhea without or without
the presence of gross rectal bleeding in infants ranging in age from birth to 6 months of
age. Children display symptoms of abdominal disress including cramping, colic, or feeding
difficulties. Emesis after feeds may also be present. Affected children display loose and
more frequent bowel movements. Stools in these patients may contain mucus as well as
microscopic or visible blood. In most patients, the diagnosis is based on an appropriate
clinical history and supporting physical exam (typically normal). Treatment involves removal
of the offending dietary antigens which include cow or soy milk protein. A small percentage
of patients (< 5%) require formal endoscopic study. The mucosa in these patients appears
erythematous, friable, and can display a patchy distribution of inflammation. Histologic
exam reveals varying degrees of eosinophic infiltration of the intestinal tissue.
Eosinophilic crypt abscesses, or collections of eosinophils within the intestine can also be
seen. Patients responding to therapy will display normalization of stool frequency,
decreased symptoms of abdominal discomfort, and an absence of gross or microscopic
intestinal bleeding.
CD23 is a protein that can be found on allergy-type white blood cells (eosinophils), as well
as on the cells that line the gastrointestinal tract. Previous studies have reported
increased levels of CD23 in infants with cow's milk allergy. CD23 is also elevated in
infants and children with allergic disease, when compared to to children without apparent
atopic disease. Moreover, the level of CD23 appears to fall in conjunction with therapy.
The development of non-invasive markers of intestinal allergy would facilitate diagnosis as
well as provide clinicians with a tool to assess patients compliance and response to
therapy. The relationship between levels of serum, urinary, and fecal CD23 levels has not
been previously studied in patients with known or suspected intestinal allergy.
Subjects in this study will be asked to provide a blood, urine, and stool sample when they
present with symptoms or either cow milk protein intolerance or eosinophilic esophagitis.
Blood will only be obtained if clinical samples are requested, and no extra blood drawing
will be required for participation in this study. Similar blood, urine, and stool specimens
will be obtained after the patient has been placed on anti-atopic therapy and is
experiencing clinical remission.
Inclusion Criteria:
Known or suspected cow milk protein intolerance Known or suspected eosinophilic
esophagitis
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
